There is finally some welcome and overdue financial relief for patients with keratoconus and other types of corneal ectasia.

As of May 1, 2018 there will be a Medicare rebate for corneal collagen crosslinking, the only proven treatment to stop the progression of keratoconus. The Medicare rebate allows greater community access to this important treatment, and in time, reduce the personal, societal and financial burden of corneal transplantation.

Currently, keratoconus is the most common reason why a corneal transplant is performed. Corneal collagen crosslinking allows stabilisation of keratoconus, and minimises the progression towards a transplant.

More details will follow shortly, but the news is welcomed for keratoconus sufferers and their families.

Read more information on Keratoconus  
Read more information on Collagen Cross-Linking